Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study
| Autor: | Janet O'Sullivan, George Thomas Budd, Silvana Martino, J Harris, J J Rinehart, R M O'Bryan, Richard G. Hahn, Martin D. Abeloff, Sylvan B. Green, Douglass C. Tormey |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Vincristine Cyclophosphamide medicine.medical_treatment Breast Neoplasms Disease-Free Survival Breast cancer Prednisone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Aged Proportional Hazards Models Chemotherapy Chi-Square Distribution business.industry Middle Aged medicine.disease United States Surgery Survival Rate Regimen Methotrexate Receptors Estrogen Fluorouracil Doxorubicin Lymphatic Metastasis Female Lymph Nodes business medicine.drug Follow-Up Studies |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(4) |
| ISSN: | 0732-183X |
| Popis: | PURPOSE To compare 1 year of therapy with continuous cyclophosphamide, methotrexate, fluorouracil (5-FU), vincristine, and prednisone (CMFVP) with a short course of treatment with a doxorubicin-based regimen in the postsurgical adjuvant treatment of patients with hormone receptor-negative, node-positive breast cancer. PATIENTS AND METHODS Five-hundred thirty-one eligible women with hormone receptor-negative, node-positive breast cancer were randomized to receive either 1 year of therapy with CMFVP or 20 weeks of therapy with four 5-week courses of treatment with 5-FU, doxorubicin, cyclophosphamide, and methotrexate (FAC-M). RESULTS At a median follow-up time of 4.9 years, the two treatment arms cannot be demonstrated to be different with respect to overall survival (stratified log-rank, P = .27). The 5-year survival rate is 64% on the CMFVP arm and 61% on the FAC-M arm. CMFVP produces marginally superior disease-free survival (P = .06). The estimated 5-year disease-free survival rate is 55% for patients treated with CMFVP as opposed to 50% for patients treated with FAC-M. CONCLUSION Neither regimen was shown to be superior in terms of overall survival. Because the disease-free survival produced by CMFVP is marginally superior to that produced by FAC-M, we do not recommend FAC-M for further investigation or for routine use. Possible implications of this study are discussed in the context of other adjuvant chemotherapy trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|